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Objectives The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of
prasugrel therapy versus tiroﬁban bolus with or without a post-bolus short drug infusion in ST-seg-
ment elevation myocardial infarction (STEMI) patients.
Background The degree and rapidity of IPA after prasugrel alone with or without concomitant gly-
coprotein IIb/IIIa inhibition in STEMI patients is unknown.
Methods A total of 100 STEMI patients randomly received prasugrel 60 mg versus 25 g/kg tiro-
ban bolus with or without post-bolus 2-h infusion of tiroﬁban, with or without concomitant prasu-
rel. IPA at light transmission aggregometry was performed throughout 24 h. The primary endpoint
as IPA stimulated with 20 mol/l adenosine diphosphate (ADP) at 30 min.
Results At 30 min, patients in the prasugrel group showed a signiﬁcantly lower IPA to 20 mol/l
ADP stimulation as compared with tiroﬁban-treated patients (36  35 vs. 87  31, p  0.0001).
Similarly, patients taking prasugrel showed a suboptimal degree of platelet inhibition for at least 2 h
compared with tiroﬁban patients. Post-bolus tiroﬁban infusion was necessary to maintain a high
level of IPA beyond 1 h after bolus administration if concomitant clopidogrel was given, whereas
the bolus-only tiroﬁban and concomitant prasugrel led to the higher and more consistent IPA levels
after both ADP and thrombin receptor-activating peptide stimuli than either therapy alone.
Conclusions Our study shows that prasugrel administration leads to a suboptimal IPA for at least 2 h in
STEMI patients. Yet, prasugrel, given in association with a bolus only of glycoprotein IIb/IIIa inhibitor, ob-
viates the need of post-bolus infusion and almost completely abolishes residual variability of IPA after
treatment. (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-
segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse [The
FABOLUS PRO trial]; NCT01336348) (J Am Coll Cardiol Intv 2012;5:268–77) © 2012 by the American
College of Cardiology Foundation
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269Given the pivotal role of the platelet in acute coronary
syndromes (ACS), measures to inhibit platelet activity are
paramount to its management (1). Over time, a growing
recognition of the various pathways driving platelet activity
has given rise to the need for multiple agents, which impart
complimentary mechanisms of action.
Blocking simultaneous platelet upstream activation via aspi-
rin and clopidogrel, a rather weak P2Y12 receptor blocker, and
downstream aggregation pathway with glycoprotein IIb/IIIa
inhibitors (GPI) has been shown to be beneficial in preventing
ischemic periprocedural complications in patients with ACS
undergoing coronary intervention (2–5).
See page 278
Yet, the recent advent of potent and fast-acting oral
P2Y12 inhibitors, such as prasugrel or ticagrelor, which are
ble to almost completely suppress adenosine diphosphate
ADP)-induced platelet aggregation (PA) (6–8), is question-
ng the additional value of GPI in contemporary practice.
Pharmacokinetic data on the effect of prasugrel admin-
stration in ACS patients are limited, however (9,10), and
here is no randomized comparison of GPI versus prasu-
rel measuring potency and rapidity of PA inhibition.
his evaluation appears particularly critical for ST-
egment elevation myocardial infarction (STEMI) pa-
ients, in whom the capability of clopidogrel to suppress
DP-induced platelet activation is largely inferior to
hat would be predicted based on assessments in stable
atients (11).
We compared the degree of platelet inhibition after
dministration of prasugrel only versus a treatment strategy
ased on tirofiban bolus with or without a post-bolus short
rug infusion, with or without concomitant prasugrel, in
TEMI patients undergoing primary percutaneous coro-
ary intervention (PCI).
ethods
Study design and patient population. The FABOLUS
RO (Facilitation through Aggrastat By drOpping or
hortening Infusion Line in patients with ST-segment
levation myocardial infarction compared to or on top of
Rasugrel given at loading dOse) study is a single-center,
pen-label, prospective randomized pharmacodynamic in-
estigation of 2 main antiplatelet treatment strategies in
atients undergoing coronary intervention for STEMI: oral
dministration of prasugrel alone at a loading dose of 60 mg
r the administration of tirofiban 25 g/kg bolus with or
without a 0.15 g/kg/min 2-h post-bolus infusion of
tirofiban with concomitant or post-infusion administration
of either 60 mg of prasugrel or 600 mg of clopidogrel (Fig. 1).
The study protocol was approved by the ethics committee
and was conducted according to the principles of the rDeclaration of Helsinki. All patients provided written informed
consent before enrollment.
Eligible subjects were those older than 18 years old,
undergoing coronary intervention for symptoms of ischemia
that were lasting at least 30 min with an electrocardio-
graphic ST-segment elevation 1 mm in 2 or more con-
tiguous electrocardiogram leads, or with a new left bundle-
branch block, and admission either within 12 h of symptom
onset or between 12 and 24 h after onset with evidence of
continuing ischemia. The exclusion criteria included admin-
istration of fibrinolytics in the previous 30 days, major
surgery within 15 days, current bleeding, or previous stroke
in the last 6 months. All patients underwent primary
angioplasty immediately after the start of the oral and/or
intravenous treatment.
Randomization. An independent study nurse performed
assignments of study treatments via a procedure employing
sealed envelopes. A 3:1:1:1 computer-generated random
sequence in blocks of 6, without
stratification and supplied by an
academic statistician was used to
treat patients with the following
4 different treatment strategies:
1) prasugrel 60 mg only; 2) tiro-
fiban 25 g/kg bolus only and
oncomitant clopidogrel 600
g; 3) tirofiban 25 g/kg bolus
only and concomitant prasugrel
60 mg; and 4) tirofiban 25 g/kg
bolus followed by 0.15 g/kg/
in 2-h tirofiban post-bolus in-
usion without any concomitant
ral P2Y12 inhibitors. At the
ime of discontinuation of the
irofiban infusion, this group of
atients was subsequently ran-
omly allocated to receive either prasugrel 60 mg or clopi-
ogrel 600 mg according to a 1:1 computer-generated
andom sequence in blocks of 4.
Study medications and interventions. Upon presentation,
patients received aspirin at 160 to 325 mg orally or 250 mg
intravenously, followed by 100 mg orally indefinitely. Pra-
sugrel was given at a 60-mg loading dose followed by 10
mg/day for at least 30 days, whereas clopidogrel was
administered at a loading dose of 600 mg followed by 75 mg
daily. Tirofiban was given as a bolus of 25 g/kg with or
without post-bolus infusion of 0.15 g/kg/min for 2 h. In
all patients, anticoagulation during the procedure was
achieved via administration of unfractionated heparin given
as a bolus of 100 U/kg, targeting an activated clotting time
of at least 300 s.
Platelet function testing. PA was performed as previously
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CI  confidence interval
GPI  glycoprotein IIb/IIIa
inhibitors
IPA  inhibition of platelet
aggregation
PA  platelet aggregation
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TRAP  thrombin receptor-
activating peptideeported (1,12) immediately before the administration of
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270tirofiban and/or oral P2Y12 receptor blockers (baseline
ample), at 15  5 min, 30  5 min, 60  5 min, 120 
5 min, and 360  5 min, and 18 to 24 h after start of the
treatment (i.e., intravenous tirofiban bolus and/or oral
prasugrel administration). Blood samples that were anti-
coagulated with 0.129 mol/l sodium citrate were collected
for platelet reactivity. Platelet-rich plasma, obtained by
centrifuging whole blood for 10 min at 70 g, was
stimulated with 5 and 20 mol/l ADP and 5 and 15
mol/l thrombin receptor agonist peptide (TRAP) (Alfa
asserman, Bologna, Italy), and aggregation was as-
essed using an AggRAM Advanced Modular System
ight transmittance aggregometer (Helena Laboratories,
eaumont, Texas). The 100% line was set using platelet-
oor plasma and the 0 baseline established with platelet-
ich plasma (adjusted from 18  109/l up to 30  109/l).
A (according to Born’s method) was evaluated consid-
ring the maximal percentage of PA in response to
timulus (Aggmax). Inhibition of PA (IPA) was defined as
Figure 1. Patient Flow and Study Design
(A) The number of patients screened and ﬁnally recruited in each study arm. (the percentage decrease in aggregation values (Aggmax) vbtained at baseline and after treatment: (%PA Tbaseline—
%PA Tafter drug)/%PA Tbaseline.
Study endpoints and statistical analysis. The primary end-
point was the IPA at light transmission aggregometry,
stimulated with 20 mol/l ADP 30 min after start of the
treatment on a superiority basis.
Key secondary endpoints in all recruited patients included
IPA after both ADP and TRAP stimuli at any measured
time point.
The primary hypothesis of the study is that the IPA after
20 mol/l ADP at 30 min will be superior in the tirofiban
rm, analyzed as an aggregate, versus the prasugrel-alone
roup.
The sample size of 100 patients was based on an
nticipated %IPA of 90% in the tirofiban group versus 80%
n the prasugrel arm, with a sigma of 0.15, an estimated
ower of 90% at a 2-sided alpha level of 0.05.
Continuous variables are shown as mean  SD and were
ompared by using the Student unpaired t test. Categorical
ws the study design and sampling schedule.ariables are presented as counts and percentages and
s
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271compared with the Fisher exact test. The kinetics of platelet
inhibition and possible differences between the 2 treatments
in the whole model or at specific time points were studied by
using a linear mixed model with linear contrast, adjusted for
the value of baseline IPA. The model selection was per-
formed using the Akaike Information Criterion, and we
assumed treatments as a fixed effect and the intercept as a
random one. To reduce the type I error probability, the p
values were adjusted according to Holm’s step-down pro-
cedure (13). To define whether significant interindividual
variability was present in response to antiplatelet treatment,
the coefficient of variability was used (coefficient of variabil-
ity  SD/mean). All analyses, carried out based on the
intention-to-treat principle, were performed using Stata,
version 9.2 (Stata Corp., College Station, Texas).
Results
Baseline and procedural characteristics. Patients were re-
cruited from April 2010 to June 2011. The 2 main study
groups (i.e., the prasugrel monotherapy group and the
Table 1. Baseline Characteristics of the Study Population
Prasugrel 60 mg
(n  52)
All Patients
(n  48)
And
Age, yrs 68 11 68 12
Male 37 (71) 32 (67)
Body mass index, kg/m2 26 4 27 4
Diabetes 11 (21) 9 (19)
Non–insulin-dependent 11 (21) 8 (17)
Insulin-dependent 0 (0) 1 (2)
Hypertension 33 (63) 30 (62)
Hypercholesterolemia 25 (48) 24 (50)
Current smokers 31 (60) 28 (58)
Creatinine, mg/dl 1.2 0.41 1.3 0.43
LV ejection fraction 48 10 47 12
Medical history
PCI 4 (8) 3 (6)
Myocardial infarction 7 (13) 9 (19)
TIA/stroke 0 (0) 0 (0)
Heart failure 0 (0) 0 (0)
Severe COPD* 4 (8) 3 (6)
Peripheral arterial disease 11 (21) 8 (17)
Carotid artery disease 2 (4) 1 (2)
Clinical presentation
Killip class 1 2 (4) 3 (6)
Systolic blood pressure 118 23 115 28
Heart rate, beats/min 79 22 81 24
Door to balloon time, min 69 34 62 31
Values are mean  SD or n (%). The p values refer to the comparison of prasugrel-alone group
requiring chronic bronchodilator therapy, or forced expiratory volume in 1 s75% of predicted.COPD chronic obstructive pulmonary disease; LV left ventricular; PCI percutaneous coronary intetirofiban arm) were well matched for all baseline and
angiographic characteristics (Table 1). Patients were pre-
dominantly male, roughly 20% had diabetes, with an aver-
age ejection fraction at transthoracic echocardiogram below
50% and a relatively stable hemodynamic profile.
No patient received treatment with an oral P2Y12 recep-
tor blocker before the index event, whereas overall, 12 (12%)
patients were regularly taking aspirin before hospital admis-
sion. The procedural success was achieved in all but 1 in
each group in whom less than Thrombolysis In Myocardial
Infarction flow grade 3 persisted despite intervention. Clin-
ical outcomes at 30 days, both in terms of ischemic and
bleeding endpoints, are shown in Table 2.
Platelet inhibition during and after PCI. Figure 2A shows the
study primary endpoint result. At 30 min, patients in the
prasugrel group showed an IPA to 20 mol/l ADP that was
ignificantly lower than the value observed in overall
irofiban-treated patients (36  35 vs. 87 31, p  0.001).
Similarly, the proportion of patients showing 80% or more
IPA to 20 mol/l ADP was 20% in the prasugrel group versus
87% in the tirofiban arm (p  0.001).
Tirofiban Bolus
p Value
grel 60 mg
16)
And Clopidogrel 600 mg
(n  14)
And 2-h Infusion
(n  18)
11 67 10 70 12 0.89
(69) 11 (78) 10 (63) 0.68
5 26 4 28 4 0.61
(19) 3 (21) 3 (19) 0.56
(19) 2 (14) 3 (19) 0.49
(0) 1 (7) 0 (0) 0.79
(63) 11 (79) 9 (56) 0.55
(50) 9 (64) 7 (44) 0.29
(63) 10 (71) 8 (50) 0.30
0.33 1.3 0.47 1.2 0.44 0.69
11 48 12 49 13 0.68
(12) 1 (7) 0 (0) 0.36
(25) 2 (14) 3 (19) 0.47
(0) 0 (0) 0 (0) 0.99
(0) 0 (0) 0 (0) 0.99
(6) 1 (7) 1 (6) 0.28
(25) 1 (7) 3 (19) 0.78
(6) 0 (0) 0 (0) 0.45
(6) 1 (7) 1 (6) 0.78
26 117 19 116 21 0.87
18 77 21 82 17 0.45
22 73 34 58 28 0.79
the tirofiban group analyzed as an aggregate. *Resulting in functional disability, hospitalization,Prasu
(n 
66
11
27
3
3
0
10
8
10
1.2
47
2
4
0
0
1
4
1
1
114
76
67
versusrvention; TIA transient ischemic attack.
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272The overall kinetics of 20 mol/l ADP–induced platelet
nhibition in the 2 main study groups confirms that the IPA
emains consistently higher in the tirofiban group, which
as analyzed as an aggregate, as compared with the
rasugrel-alone arm, through the first 2 h of treatment (p
.001 for the trend). It then does not differ at 6 h due to an
ncrease in PA inhibition by prasugrel and a slight IPA
ecline in the tirofiban group, whereas at the 18- to 24-h
ime point, due to a further IPA decline in the tirofiban
roup, the degree of platelet inhibition was in turn signifi-
antly higher in the prasugrel-only group (Fig. 2B). Inter-
stingly, patients treated with both tirofiban and prasugrel,
ither concomitantly or at the time of infusion discontinu-
tion, display a similar IPA at the 18- to 24-h time point as
ompared with patients receiving prasugrel only (Fig. 2C),
hereas the decline in platelet inhibition in the tirofiban
roup observed at the 18- to 24-h time point was entirely
riven by the subset of patients receiving concomitant or
ost-infusion clopidogrel (Fig. 2D). At 18 to 24 h, patients
n the tirofiban group who had also received prasugrel (84.1 1
.0% in the tirofiban bolus  2-h infusion group; 68.0 
27.1% in the tirofiban bolus-only group) displayed signifi-
cantly higher IPA than patients treated with clopidogrel
(23.0  17.1% and 34.1  29.2%, respectively, p  0.03 at
post hoc analysis for both) (Fig. 2D). Finally, patients
receiving tirofiban tended to have a higher degree of platelet
inhibition if concomitantly treated with prasugrel as com-
pared with those with clopidogrel throughout the first 6 h
(Fig. 2D) even if the difference in %IPA analyzed separately at
various time points never reached any statistical significance.
Consistent overall kinetics of platelet inhibition was
observed after 5 mol/l ADP (Fig. 3).
The overall kinetics of 15 mol/l TRAP-induced platelet
nhibition in the 2 main study groups shows that the IPA
as constantly higher in the tirofiban group, when analyzed
Table 2. Clinical Outcomes at 30 Days
Prasugrel 60 mg
(n  52)
All Patients
(n  48)
Death 4 (7.7) 4 (7.7)
Reinfarction 1 (1.9) 0 (0)
Urgent TVR 1 (1.9) 0 (0)
Death, reinfarction, or urgent TVR 5 (9.6) 4 (7.7)
Deﬁnite stent thrombosis 1 (1.9) 0 (0)
Deﬁnite or probable stent thrombosis 2 (3.8) 0 (0)
Intracranial bleeding 1 (1.9) 0 (0)
TIMI major bleed 2 (3.8)* 0 (0)
TIMI minor bleed 0 (0) 1 (2.1)
TIMI minimal bleed 0 (0) 1 (2.1)
Values are n (%). *Given by an intracranial bleeding and 1 gastrointestinal bleed that required 2 U o
TIMI Thrombolysis In Myocardial Infarction; TVR target vessel revascularization.s an aggregate, as compared with the prasugrel-alone arm, Fhrough the first 6 h of treatment (p  0.001 for the trend),
whereas it significantly dropped in the tirofiban group at 18
to 24 h, and at this time point, it did not differ anymore as
compared with the prasugrel alone–treated patients. In
patients receiving prasugrel-alone therapy, the IPA did not
change over time (Fig. 4A). The effect of tirofiban, either
administered as a bolus-only regimen or followed by 2-h
infusion on top of prasugrel as compared with prasugrel
alone is shown in Figure 4B.
As previously noted for ADP-induced IPA, patients
receiving tirofiban tended to have a higher degree of
TRAP-induced platelet inhibition if concomitantly treated
with prasugrel as compared with those with clopidogrel
throughout the first 6 h (Fig. 4C) even if the difference in
IPA at various time points never reached statistical signifi-
cance. At 18 to 24 h, IPA dropped significantly as compared
with previous time points in all tirofiban groups apart from
those receiving the tirofiban bolus and 2-h drug infusion
followed by prasugrel administration (Fig. 4C).
Consistent overall kinetics of platelet inhibition was
observed after 5 mol/l TRAP (Fig. 4D).
Effect of simultaneous administration of tiroﬁban and prasu-
grel versus either treatment alone. To explore the additive
alue of a near-total inhibition of upstream platelet activa-
ion and downstream PA as compared with either strategy
lone on the degree of ADP- and TRAP-induced ex vivo
latelet inhibition, IPA obtained at various time points
ithin 30 min after tirofiban bolus–only administration and
ithin 2 h after bolus and 2-h infusion was analyzed as an
ggregate and divided into the tirofiban-alone group if no
2Y12 oral receptor blocker or clopidogrel was administered
ersus tirofiban plus prasugrel group if prasugrel was admin-
stered concomitantly. IPA obtained at various time points
fter prasugrel-alone therapy was also cumulatively analyzed
nd contrasted with the 2 tirofiban groups. As shown in
Tirofiban Bolus
And Prasugrel 60 mg
(n  16)
And Clopidogrel 600 mg
(n  14)
And 2-h Infusion
(n  18)
2 (12.5) 2 (14.3) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
2 (12.5) 2 (14.3)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
1 (6.2) 0 (0) 0 (0)
0 (0) 1 (7.1) 0 (0)
lood cell transfusion.f red bigure 5A, cumulative IPA obtained after 20 mol/l ADP
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273or 15 mol/l TRAP was significantly higher after concom-
itant tirofiban and prasugrel (96.1  3.1% [95% confidence
interval (CI): 95.0% to 97.2%]; 93.0 7.1% [95% CI: 91.1% to
4.2%], respectively) administration than after prasugrel
50.2  34.0% [95% CI: 46.1% to 54.2%]; 31.2  29.1%
95% CI: 27.0% to 34.2%], respectively) or tirofiban alone
82.4 33.1% [95% CI: 74.1% to 90.4%]; 76.1 35.0% [95%
I: 67.0% to 84.1%], respectively). Interestingly, combined
pstream and downstream blockade of both platelet activation
nd aggregation led to a very consistent level of platelet
nhibition after both ADP or TRAP stimuli, with coefficients
f variability after tirofiban and prasugrel being at least 10 time
imes lower (0.03 and 0.07, respectively) than those observed
fter tirofiban (0.40 and 0.46, respectively) or prasugrel alone
0.68 and 1.07, respectively) therapy (Fig. 5B).
iscussion
Our study is the first to our knowledge to assess the
0
10
20
30
40
50
60
70
80
90
100
Prasugrel TirofibanBolus  Infusion
CV: 0.97 CV: 0.36
%
IP
A
 a
t
30
'
to
 2
0
m
ol
/L
 A
D
P
15' 30' 1 H 2 H 6 H 18-24 H
0
10
20
30
40
50
60
70
80
90
100
110
Prasugrel
Bolus+Prasugrel
*
P<0.0001 for the trend
Time after Start of the Treatment
Bolus+2H Infusion Prasugrel
* * * * * * *
%
IP
A
 t
o
20
m
ol
/L
 A
D
P
A
C
Figure 2. Kinetics of Platelet Inhibition Over Time After 20 mol/l ADP
(A) Primary endpoint analysis; percentage of platelet inhibition (%IPA) after 20
denotes the %IPA coefﬁcient of variability, which has been calculated as the S
denote mean values; (B) %IPA in the tiroﬁban group versus prasugrel alone; (C
sus the prasugrel-alone group; (D) %IPA in patients treated with tiroﬁban, with
*p  0.05 versus %IPA measured in the prasugrel-alone group at post hoc andifferential degree of platelet inhibition obtained after eitherADP and TRAP stimulation following prasugrel therapy,
tirofiban therapy administered as bolus only or bolus fol-
lowed by 2-h infusion, or both treatments given simultane-
ously. Importantly, at variance with previous studies assess-
ing the pharmacokinetics and pharmacodynamics of
prasugrel (6,14,15), we focused on STEMI patients under-
going primary PCI.
The results of our study can be summarized as follows:
1. The degree of early platelet inhibition achieved after a
60-mg loading dose of prasugrel is suboptimal at least for
the first 2 h in STEMI patients undergoing primary PCI.
2. The administration of tirofiban, given as a high-dose
bolus only, leads to a high degree of platelet inhibition
for at least 1 h on top of either a clopidogrel or
prasugrel loading dose. A 2-h post-bolus tirofiban
infusion achieves a sustained degree of platelet inhi-
bition for up to 6 h post-bolus.
3. The administration of high-dose bolus tirofiban and
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274prasugrel alone fails to provide complete platelet
inhibition. Moreover, concomitant administration of
tirofiban bolus only and prasugrel allows immediate,
sustained, and consistent platelet inhibition through-
out 24 h.
4. The capability of prasugrel to inhibit thrombin-
induced platelet activation, mimicked in our study by
the use of TRAP, was shown to be limited. By
contrast, tirofiban, by blocking the common final
pathway mediating aggregation, that is, glycoprotein
IIb/IIIa receptor, is a strong TRAP-induced platelet
inhibitor.
5. Simultaneous near-total inhibition of upstream plate-
let activation via prasugrel and downstream PA with
tirofiban led to a significantly higher degree of both
ADP- and TRAP-induced PA than tirofiban alone.
Importantly, the blocking of glycoprotein IIb/IIIa
receptor, with simultaneous potent P2Y12 receptor
inhibition, led to an extraordinary low interindividual
variability in response to both ADP and TRAP platelet
activation stimuli.
number of studies have shown that prasugrel, when given
t a loading dose of 60 mg in either healthy volunteers or
atients with stable coronary artery disease, provides a very
igh and consistent level of platelet inhibition after ADP
ithin 30 min after ingestion (6,14,15). Yet, prasugrel is
urrently approved for ACS patients only, in whom the
egree of platelet reactivity is known to be higher and in
hom, especially in STEMI patients, the pharmacokinetics
f another oral P2Y12 blocker, clopidogrel, has been shown
to be unfavorable compared with stable patients (11). Our
study shows for the first time that prasugrel 60 mg provides
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Figure 3. Kinetics of Platelet Inhibition Over Time After 5 mol/l ADP
*p  0.05 versus %IPA measured in the prasugrel-alone group at post hoc
analysis. Vertical bars represent SD of the mean value. Abbreviations as in
Figure 1.limited inhibition of ADP- or TRAP-induced PA withinthe first 2 h after drug administration in our patient
population. Importantly, this is the time frame in which
STEMI patients are expected to receive PCI. This finding
carries relevant clinical and pathophysiological implications
and emphasizes the importance of the intravenous route to
deliver effective inhibition of platelet activity in critically ill
patients, such as those presenting with STEMI.
Previous comparative or placebo-controlled studies on
GPIs (16,17) or oral P2Y12 blockers (18) have consistently
hown the value of intensified platelet inhibition at the time
f PCI to minimize ischemic complications. Whether and
or how long nearly complete platelet inhibition after
oronary stenting is truly needed is far less clear. This is the
ationale for testing in our study 2 different tirofiban
egimens, i.e., bolus-only administration or bolus followed
y 2-h infusion, which could fully inhibit PA during the
ourse of the procedure.
GPI given as bolus only or bolus and short post-bolus
nfusion regimen immediately before PCI, by fully blocking
latelet activity at the time of stenting while allowing
hereafter a gradual bridging to oral P2Y12 receptor blocker,
may represent an appealing strategy to retain the well-
established ischemic protection from GPIs and improve
their safety profile. Our study shows that tirofiban, admin-
istered as a 25 g/kg bolus only on top of 600-mg
lopidogrel and followed by a short 2-h infusion provides
ear-complete ADP- or TRAP-induced platelet inhibition
or at least 6 h. Interestingly, on top of 60-mg prasugrel, a
irofiban bolus–only regimen, irrespective of post-bolus
nfusion, achieves immediate and sustained near-total plate-
et inhibition throughout 24 h. The advent of potent oral
2Y12 receptor blockers, such as prasugrel, may therefore
justify from a mechanistic standpoint the use of GPI given
as bolus only. In contemporary practice, on-label prolonged
GPI post-bolus infusion of 12 to 24 h and up to 48 h may
end up increasing the risk of adverse events, including
bleeding and thrombocytopenia without providing addi-
tional ischemic benefit. Studies further investigating this
topic are warranted and are under way.
A growing recognition of the various pathways driving
platelet activity has given rise to the development of multiple
agents able to inhibit PA. Currently, cyclooxygenase (COX)-1–
mediated and ADP-mediated platelet activation are the
only upstream pathways that can be modulated via specific
antiplatelet therapy.
Thrombin is the most potent known platelet activator,
which may easily displace platelet inhibition carried out via
alternative mechanisms, such as COX-1 or ADP P2Y12
inhibition (19).
Although protease-activated receptor-1 oral antagonists
are being developed in phase II and phase III studies (20),
the administration of a GPI, by acting downstream on the
final common pathway for aggregation, is the only currently
available antiplatelet agent able to modulate thrombin-
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275induced platelet activation. Indeed, our study confirms that
even a potent P2Y12 receptor inhibitor, such as prasugrel,
when given alone, has limited activity on this pathway.
An intriguing observation we made is that the simulta-
neous inhibition of the P2Y12 receptor via prasugrel and the
lycoprotein IIb/IIIa receptor via tirofiban provides com-
lementary benefit in terms of both magnitude and consis-
ency of ADP- or TRAP-induced PA. This finding is new
nd deserves attention. In the Clopidogrel Loading With
ptifibatide to Arrest the Reactivity of Platelets (CLEAR-
LATELETS) study (21), no discernible effect of clopi-
ogrel at either a 300- or 600-mg loading dose was observed
n patients receiving an Food and Drug Administration–
pproved eptifibatide regimen 3 or 8 h after drug infusion.
his may be explained by taking into account the different
egree of platelet inhibition exerted by clopidogrel, a rela-
ively weak P2Y12 receptor blocker, and by a properly dosed
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Figure 4. Kinetics of Platelet Inhibition Over Time After 5 or 15 mol/l TR
(A) Percentage of platelet inhibition (%IPA) in the tiroﬁban group versus prasu
(B) %IPA in patients treated with both tiroﬁban bolus with or without post-bo
(C) %IPA in patients treated with tiroﬁban, with or without infusion and with o
group versus prasugrel-alone group after 5 mol/l TRAP. *p  0.05 versus %IP
resent SD of the mean value.GPI in this study, which almost completely suppresses PA. bContrary to clopidogrel, prasugrel is converted to an active
metabolite in a much more efficient manner and provides a
much more potent P2Y12 receptor inhibition. Despite
tirofiban being much quicker and potent, as clearly shown in
our head-to-head comparison, prasugrel 60 mg was shown
to slightly, but significantly, improve the performance in
terms of inhibition of ADP-induced platelet activation as
compared with tirofiban bolus or tirofiban bolus and post-
bolus infusion. Of particular interest is the observation that
the addition of prasugrel to tirofiban led to an impressively
low interindividual variability as captured by the coefficient
of variability of the degree of platelet inhibition. This may
be due to the synergistic effect of near-total blocking of
platelet activating pathways both upstream via a potent oral
P2Y12 inhibitor, such as prasugrel, and downstream, via
irofiban, a potent glycoprotein IIb/IIIa inhibitor. This
2-hit hypothesis” is new and potentially of great relevance
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276protein IIb/IIIa receptors has been previously documented
to be associated with differential clinical outcomes (22,23).
The hypothesis that local infusion of abciximab-bolus only will
ecrease infarct size compared with no treatment on top of P2Y12
inhibition is also being tested in the INFUSE–Anterior Myocar-
dial Infarction (AMI) study (NCT00976521).
Study limitations. Our study was not powered to assess the
efficacy or safety profile of combining prasugrel with tiro-
fiban with respect to either drug alone. Additional studies
are also warranted to investigate the role of concomitant
bivalirudin in both ADP- and TRAP-induced PA after
prasugrel or clopidogrel administration. Due to the very
tight schedule for blood sampling in our study, only the
patients who presented during on-hours were recruited.
Conclusions
Our study shows for the first time that prasugrel given as a
loading dose of 60 mg leads to a suboptimal degree of
platelet inhibition after both ADP- and TRAP-induced
platelet activation for at least 2 h after drug administration
in STEMI patients. Tirofiban, given as bolus only or bolus
followed by 2-h infusion either on top of clopidogrel or
prasugrel, leads to a significantly higher degree of platelet
inhibition as compared with prasugrel alone. The concom-
itant administration of a GPI bolus–only regimen and
prasugrel is a promising treatment strategy, which allows
immediate and sustained inhibition of platelet activation
and is associated with a remarkably low interindividual variability
in responsiveness to both ADP and TRAP stimuli.
This treatment combination warrants further testing in
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Figure 5. Additive Value of Concomitant Tirofiban and Prasugrel Administra
(A) Cumulative mean %IPA measured at various time points after 20 mol/l A
concomitant tiroﬁban and prasugrel therapy. (B) Cumulative mean coefﬁcient
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